Ocular Therapeutix, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Amounts are in millions of dollars unless stated otherwise. The company develops and commercializes ophthalmic therapies using its ELUTYX hydrogel technology. DEXTENZA is its sole commercial product; its other programs remain in development.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Net product revenue | $13.214 | $12.498 |
| Collaboration revenue | $0.160 | $0.689 |
| Total revenue | $13.374 | $13.187 |
| Research and development | $14.747 | $13.100 |
| Selling and marketing | $10.835 | $9.063 |
| General and administrative | $9.127 | $7.557 |
| Operating loss | $(22.549) | $(17.833) |
| Net loss | $(30.318) | $(12.542) |
| Operating cash used | $(19.973) | $(18.600) |
- Product revenue increased about 6%; total revenue rose about 1%. DEXTENZA generated all product revenue. Product cost was $1.214 million, implying an approximate product gross margin of 91% before operating expenses.
- Cash and cash equivalents were $79.026 million at quarter-end; cash, cash equivalents and restricted cash totaled $80.790 million. Cash declined $23.274 million during the quarter, including $3.379 million of capital expenditures.
- Management estimates existing cash will fund planned operations, debt service and capital expenditures into mid-2024, excluding planned pivotal OTX-TKI trials, which it does not intend to start without additional funding. The estimate depends on assumptions about DEXTENZA sales, spending and development pace.
- Debt included $25.0 million principal under the fully drawn credit facility and $37.5 million principal of 2026 convertible notes, plus $9.191 million accrued note interest. The credit facility rate was 11.8% at March 31; interest-only payments run through May 2024, with principal repayment scheduled in 2024–2025. The convertible notes carry a 6% stated rate and mature in 2026 unless earlier converted, repurchased or redeemed.
- Current assets were $107.162 million and current liabilities were $29.715 million. Stockholders’ equity fell to $9.711 million from $35.379 million at year-end 2022.
Changes, outlook and notable items
- Operating expenses rose $4.903 million year over year, led by higher R&D, selling and marketing, and G&A spending. Net loss widened substantially, in part because a $6.563 million non-cash derivative remeasurement loss replaced the prior-year $6.958 million gain. The derivative liability increased to $12.914 million; its fair-value movement does not affect expected cash outflows.
- Management reported more than 34,000 DEXTENZA billable units sold into the market in Q1, up approximately 25% from Q1 2022 and 8% from Q4 2022. These distributor-to-provider unit figures can differ from recognized revenue because of distributor stocking. Gross-to-net provisions were 28.1% of gross product sales, versus 21.9% a year earlier.
- Management expected OTX-TKI wet AMD pivotal trial initiation as early as Q3 2023, subject to financing; a DR Phase 1 readout as early as Q4 2023 and possible Phase 3 initiation as early as Q1 2024, subject to data and financing. OTX-TIC Phase 2 topline results were expected in Q4 2023. These are forward-looking expectations, not assured outcomes.
- OTX-TIC enrollment in the 5 μg Phase 2 arm was stopped after IOP elevations in six subjects; enrollment continued in the 26 μg and DURYSTA arms. The 2021 OTX-CSI Phase 2 trial did not meet its primary endpoint of increased tear production versus vehicle; formulation work continues.
- In the U.S. OTX-TKI wet AMD Phase 1 interim results, 73% of treated subjects remained rescue-free through Month 10 and treatment burden was reported 92% lower than subjects’ historical injection regimens. The filing describes these as interim, early-stage findings; one endophthalmitis serious adverse event followed a protocol-required aflibercept injection and was assessed as procedure-related.
- The company drew and repaid a $2.0 million short-term protective advance in March following Silicon Valley Bank’s closure. It amended its credit agreement to use SOFR-based interest provisions and, in May 2023, obtained permission to hold up to 50% of cash and equivalents at institutions other than SVB.
- Cash remained concentrated at two financial institutions, with balances above FDIC insurance limits. Three specialty distributors represented 90% of Q1 gross product revenue and 92% of quarter-end accounts receivable. The company also relies on a limited number of third-party manufacturers.
- AffaMed’s China clinical-trial authorization for DEXTENZA, announced in April 2023, triggered a $1.0 million milestone invoiced after quarter-end. No material legal proceedings or subsequent events were reported; the filing notes ordinary-course indemnification obligations whose maximum potential payments are not determinable.
Important facts for investors to verify
- Whether DEXTENZA sales growth, reimbursement access and gross-to-net deductions support management’s cash runway assumptions.
- Timing, financing and clinical results for OTX-TKI pivotal studies, and the upcoming OTX-TIC Phase 2 readout.
- Cash burn, planned capital expenditures and ability to raise capital before the projected mid-2024 runway endpoint.
- Credit facility covenants, interest costs, repayment schedule and the convertible notes’ accrued interest, conversion terms and derivative valuation.
- Exposure to distributor concentration, manufacturing interruptions and uninsured cash balances.